Evidence map›Paper›PMID 33881598›Full record

ReviewJournal of neurology2022

Gastrointestinal dysfunction in Parkinson's disease: molecular pathology and implications of gut microbiome, probiotics, and fecal microbiota transplantation.

Vinod Metta, Valentina Leta, Kandadai Rukmini Mrudula, L K Prashanth, Vinay Goyal, Rupam Borgohain, Guy Chung-Faye, K Ray Chaudhuri

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Journal of neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07316751 (Italian Translation and Validation of the GIDS-PD Scale for Parkinson's Disease), which is not on this map. Cited by 79 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 4 pooled it
9.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07316751 recruitingnot on this mapstarted 2025, after this paper: background citation

Italian Translation and Validation of the GIDS-PD Scale for Parkinson's Disease

TypeobservationalSponsorFondazione I.R.C.C.S. Istituto Neurologico Carlo BestaRan2025 to 2028Enrolled190ConditionsPARKINSON DISEASE (Disorder), Parkinson Disease
3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 4 syntheses or guidelines pooled it, 120 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. International journal of molecular sciences · 2024
    Pooled it
  5. Review
  6. Cellular and systemic modifiers of alpha-synuclein proteostasis.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2026
    Review
  7. Article
  8. Review
  9. Branched-chain amino acids ameliorate CD4NPJ Parkinson's disease · 2026
    Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Vinod MettaDepartment of Neurosciences, King's College London, Institute of Psychiatry, Psychology and Neuroscience, London, UK. Vinod.metta@nhs.net.ORCID http://orcid.org/0000-0002-8970-8595
Valentina LetaDepartment of Neurosciences, King's College London, Institute of Psychiatry, Psychology and Neuroscience, London, UK.
Kandadai Rukmini MrudulaNizams Institute of Medical Sciences, Hyderabad, India.
L K PrashanthVikram Hospitals Bengaluru, Bangalore, India.
Vinay GoyalMedanta Institute of Neurosciences, New Delhi, India.
Rupam BorgohainNizams Institute of Medical Sciences, Hyderabad, India.
Guy Chung-FayeDepartment of Gastroenterology, King's College London, Institute Parkinson's Foundation Centre of Excellence, King's College Hospital, London, London, UK.
K Ray ChaudhuriDepartment of Neurosciences, King's College London, Institute of Psychiatry, Psychology and Neuroscience, London, UK.
King's College London · GBNizam's Institute of Medical Sciences · INMedanta The Medicity · INVikram Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastrointestinal symptoms and gut dysbiosis may occur before the onset of motor symptoms in Parkinson's disease (PD). Prediagnostic and prodromal features, such as constipation and α-synuclein pathology, can be detected several years before the clinical diagnosis of PD and have the potential to develop as early PD biomarkers. Environmental toxins and gut dysbiosis may trigger oxidative stress and mucosal inflammation, and initiate α-synuclein accumulation in the enteric nervous system, early in PD. Chronic gut inflammation can lead to a leaky gut and systemic inflammation, neuro inflammation, and neuro degeneration via gut-vagus-brain signaling or through blood-brain barrier permeability. Concepts regarding the gut-brain signaling in PD pathogenesis are changing rapidly and more investigation is required. The gut microbiota interacts with the human body by modulating the enteric and central nervous systems, and immune activity. Understanding the immune responses between gut microbiota and human body might help in elucidating the PD pathogenesis. As changes in gut microbiota composition might be associated with different clinical phenotypes of PD, gut microbiota-modulating interventions, such as probiotics and fecal microbiota transplantation (FMT), have the potential to restore the gut dysbiosis, reduce inflammation, and possibly modulate the clinical PD phenotype.

Indexed as

Gastrointestinal MicrobiomeParkinson DiseaseProbioticsFecal Microbiota TransplantationHumansPathology, MolecularFecal microbiota transplantationGastrointestinal dysfunctionGut microbiotaParkinson’s diseaseProbiotics

Identifiers

PMID33881598
OpenAlexW3154889217

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.